Journal of Clinical Oncology
Articles in this Issue
Genomic alterations in intraductal prostate cancer: Insights from the Genomic Umbrella Neoadjuvant study (GUNS) in high-risk localized disease.
417 Background: Intraductal carcinoma of the prostate (IDC) is an aggressive histological variant of prostate cancer, characterized by the presence of mal...
Access to immune checkpoint inhibitors (ICI) in patients randomized to the control arm of ICI phase 3 trials in urothelial and renal cell cancers.
448 Background: We investigated access to ICIs in patients (pts) randomized to the control arm across positive phase 3 trials for renal cell carcinoma (RC...
HIF2α gene expression and clinical outcomes in patients with clear cell renal cell carcinoma with and without sarcomatoid differentiation.
539 Background: Clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation (sRCC) is associated with poor survival. Recent studies have show...
Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.
LBA138 Background: Mevrometostat (M) is a potent and selective inhibitor of EZH2. Dose exploration of M + enzalutamide (E) + androgen deprivation therapy...
Radical cystectomy in female patients: Does the urinary diversion type affect postoperative complications?
752 Background: Data is limited on the possible impact of urinary diversion (UD) type on post cystectomy complications, particularly in women. This study...
Mental health monitoring in clinical trials for FDA-approved genitourinary cancer treatments: A decade review.
696 Background: The treatment landscape for genitourinary (GU) malignancies, including bladder, kidney, and prostate cancers, has evolved with several nov...
Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.
219 Background: PROpel (NCT03732820) met its primary endpoint showing statistically significant investigator-assessed (INV) radiographic progression-free...
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for urothelial cancer.
680 Background: The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is a tool used to describe a cancer patient’s functional status and...
Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study.
706 Background: Avelumab 1LM is standard of care for patients with la/mUC without disease progression after 1L platinum-based chemotherapy (PBC) based on...
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
667 Background: A critical need persists to develop treatments for BCG-unresponsive (BCG-U) non-muscle invasive bladder cancer (NMIBC) patients (pts). The...
Evaluating RSPO2 activation and its association with outcomes and potential role as a driver in double-negative prostate cancer (DNPC).
236 Background: Several aggressive tumor variants have emerged since the broad use of 2nd generation androgen therapies for metastatic prostate cancers (m...
Concordance of circulating tumor DNA and imaging surveillance in patients with urothelial carcinoma and renal cell carcinoma post-immunotherapy.
597 Background: Early detection of recurrence in urothelial carcinoma (UC) and renal cell carcinoma (RCC) may improve patient outcomes. Conventional imagi...
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
476 Background: Brain metastasis (BM) is an adverse prognostic indicator and associated with poor survival for patients with metastatic renal cell carcino...
Targeting the soluble epoxide hydrolase (sEH) enzyme to relieve painful docetaxel-induced peripheral neuropathy.
126 Background: Docetaxel is an important chemotherapeutic agent used for the treatment of several cancers, including metastatic prostate cancer. Unfortun...
Influence of MRIs performed in a 6-week interval on the histopathological detection of prostate cancer with different PIRADS classifications: A real-world data analysis.
334 Background: In the early phases of MRI-guided prostate biopsies, it was often necessary to perform an additional in-house multiparametric MRI after an...
Intra-patient comparison of urinary radioactivity after <sup>18</sup> F-piflufolastat and <sup>18</sup> F-flotufolastat PET in men with low PSA biochemical recurrence of prostate cancer who have had radical prostatectomy.
TPS272 Background: Prostate-specific membrane antigen (PSMA)-targeting positron emission tomography (PET) radiopharmaceuticals enable early detection of m...
Survival outcomes of de novo mHSPC based on hemoglobin A1C and ARPI therapy.
139 Background: While there has been no prospective studies, enzalutamide (enza) has better overall survival, fewer adverse events, risk of progression, a...
Biomarker testing patterns among patients newly diagnosed with prostate cancer in a community oncology network.
229 Background: Prostate cancer guidelines recommend that clinicians order biomarker testing for patients with metastatic prostate cancer. In addition, te...
Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer.
525 Background: HRQoL tools and adverse event criteria were designed around outdated therapies and require re-evaluation in the era of immune checkpoint i...
Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers.
209 Background: Prostate cancer (PC) progression is driven by aberrant activity of the androgen receptor (AR) or its associated ligands - androgens. Dysre...
Detection of mutations in homologous recombination repair (HRR) pathway genes using liquid biopsy in metastatic, castration-resistant prostate cancer (mCRPC) patients without tumor tissue availability.
98 Background: Accurate detection of mutations in HRR pathway genes among patients with mCRPC is essential for selecting patients who would benefit with p...
Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model.
192 Background: Early PSA nadir after systemic therapy in mHSPC is a predictor of overall survival. There are no prediction models that have been validate...
Difference in renal cell carcinoma (RCC) prevalence between kidney transplant versus other solid organ transplant patients.
520 Background: The annual incidence of renal cancer is 0.02% among the general United States population. End stage renal disease (ESRD) and exposure to d...
Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.
666 Background: CAUBC (any patients with node positive, metastasis positive or inoperable T4 disease) arising in YOUC is a challenging disease with signif...
Differences in incidence and clinicopathologic features of secondary bladder cancer after long-term follow-up of brachytherapy and radical prostatectomy for localized prostate cancer.
381 Background: Although there studies have been reported that brachytherapy (BT) for prostate cancer is associated with an increased incidence of metachr...